Jonathan Curio

MD. Fascinated by Interventional Cardiology | Heart Center University Cologne @UKKoeln | Editorial Board @PCRonline | Visual Media Editor @JACCJournals #JACCCR

[Jonathan Curio @CurioJonathan]

#TreatTR @azeemlatib @AntonioMangieri @g_lanzillo @PCRonline @Ortega_Paz #EAPCI

[JACC Journals @JACCJournals]

Future percutaneous approaches might address the large unmet clinical need of severe #vhdTR. Learn more in #JACC. https://t.co/0vtzwwZOHC

[PCRonline 🫀 @PCRonline]

“Innovators Day is not only for physicians.”

In this interview with @CurioJonathan, @AndreaScotti21 explains how #PCRID brings together physicians, entrepreneurs, innovators and investors to discuss the future of cardiovascular innovation. 🚀🫀

#EuroPCR #PCRID

[Jonathan Curio @CurioJonathan]

The 3 innovations competing for #EuroPCR 2️⃣0️⃣2️⃣6️⃣ #PCRID Innovators Day @PCRonline Jon DeHaan Foundation award nicely highlighted by @AndreaScotti21 ⤵️

➡️Join #EuroPCR Ceremony on Thursday, 10:15, Main Arena, to learn the 200k grant winner

@azeemlatib @nickaram @nicolo_piazza

[Andrea Scotti @AndreaScotti21]

🏆 Jon DeHaan Foundation Award — #PCRID 2026

🔹 TriFlo — TR Tx (Sarkar)

🔹 eVAD System — extravascular LV/RV assist device (Krucoff)

🔹 CARLEN System — first-in-human for functional MR (Kodali)

Three innovations. One prize. Which would you back?

#EuroPCR #treatTR #Innovation

[Jonathan Curio @CurioJonathan]

A 1st row seat at the table w/ all key stakeholders - unique experience in Exchange Sessions at #EuroPCR #PCRID @PCRonline Innovators day

➡️Early stage funding, AI in innovation, late-stage reimbursement, Chinese innovation

@AndreaScotti21 @azeemlatib @nickaram @nicolo_piazza

[Andrea Scotti @AndreaScotti21]

Disrupting the aorta and valves: the next transcatheter wave

🔸ТТЗA - transcatheter ascending ao repair
De Marco

🔸InFlow - polymeric transcatheter AV Buszman

🔸TriClover - TV clover repair
De Bonis

🔸ReNiva Trapeze - posterior leaflet replacement
Bapat

#EuroPCR #PCRID

[Jonathan Curio @CurioJonathan]

#treatTR beyond T-TEER vs. TTVR:

🎯M. deBonis w/ TriClover at #EuroPCR #PCRID @PCRonline
🎯 Transcath suture based tripple-orifice
🎯Reliable clover shape achieved in animals

➡️Design refinements & in-vivo/animal planned

@AndreaScotti21 @azeemlatib @nickaram @nicolo_piazza

[Andrea Scotti @AndreaScotti21]

Day 1 of #EuroPCR Week: #PCRID 2026 in Paris.

🌐Physicians, engineers, VCs, and entrepreneurs in the same room debating the future of cardiovascular innovation.

🏆Sessions on SH, HF, and venture capital, plus the Jon DeHaan Foundation Award for early-stage innovations.

[Jonathan Curio @CurioJonathan]

#EuroPCR 2026 is here & yet has its 1st highlight: #PCRID @PCRonline Innovators Day💡

🎯Innovation shaping the future #IC field
🎯Tracks on paths from idea to FIH to clinical practice

➡️If in Paris, join at Palais Congres

@AndreaScotti21 @azeemlatib @nickaram @nicolo_piazza

[PCRonline 🫀 @PCRonline]

Innovation is thriving in #interventionalcardiology, so make sure you follow the news from PCR Innovators Day, happening Monday 18 May in Paris.

@CurioJonathan and @AndreaScotti21 will keep you up to date with all the buzz 🔥and hot news via their #PCRID #SoMe coverage!

@azeemlatib @nickaram @nicolo_piazza
#EuroPCR

[PCRonline 🫀 @PCRonline]

🔥#ACC26 Late-breaking trials 🔥: TRISCEND II

🔗https://t.co/psnD3i0LTV

@CurioJonathan .provides his take ✍️on the results of this international, multi-centre, randomised, controlled trial that enrolled 400 patients with symptomatic severe TR.

Presented by Vinod H. Thourani in New Orleans.

#interventionalcardiology #clinicaltrial #cardioX

[PCRonline 🫀 @PCRonline]

🔥#ACC26 Late-breaking trials 🔥: PRO-TAVI

🔗https://t.co/1mXXgUoUWi

@CurioJonathan provides his take ✍️on this trial that evaluated whether deferral of routine PCI in patients undergoing TAVI is non-inferior in comparison to TAVI with preceding PCI,

The results 📊 were presented by Michiel Voskuil in New Orleans and simultaneously published in @TheLancet.

#interventionalcardiology #clinicaltrial #CardioX #TAVR

[PCRonline 🫀 @PCRonline]

My Toolkit 🧰⚙️🪛:How to perform ELASTA-Clip: lacerating M-TEER devices to enable TMVR

🔗https://t.co/MBO0l9E9E3

Recurrent mitral regurgitation after M-TEER can create a challenging scenario. Discover the ELASTA-Clip technique and its key steps to enable TMVR!

@CurioJonathan & Matti Adam provide a step-by-step guide to navigate these complex redo cases. Reviewed by @parma.

#interventionalcardiology #cardioX #medtwitter

[CRT Meeting @CRT_meeting]

Tricuspid regurgitation patients who receive TTVA with the Cardioband see positive cardiac remodeling and functional improvement a year post-procedure, according new a new German real-world study. Read more on #CRTonline. https://t.co/thiG0ABJ2g

[EuroIntervention @EuroInterventio]

#EIJonAir - Analysis of the NOTION-2 trial https://t.co/zEFHiAyQw9

[Dr. Gilbert Tang @GilbertTangMD]

Mild PVL after #TAVR is NO LONGER acceptable, especially in low/intermediate risk and younger patients. In #JACCINT @JACCJournals the OCEAN-TAVI registry showed long-term higher mortality and TAV failure even with mild PVL. Minimizing PVL when safe should be routine now.

2 seminar studies including one from our @MountSinaiHeart @MountSinaiNYC @IcahnMountSinai by @ParasuramMD et al shows underexpanded balloon-expandable #TAVR risks early failure and ROUTINE DOUBLE-TAP post dilatation improves balloon-expandable TAV expansion!

Like #PCI where you routinely pre-dilate a lesion and post dilate the stent to avoid ISR, and pre- and post-dilating in redo-PCI for ISR, optimizing valve frame expansion, minimizing PVL during index #TAVR is now paramount to confer durability, REGARDLESS of the type of TAV: balloon-expandable and self-expanding. Best view to do post-dilatation is at RAO CAU with TAV parallax removed to visualize the SHORT AXIS of the native annulus to evaluate frame geometry. WE MUST ACT NOW!

OCEAN-TAVI registry on mild PVL and TAVR long-term outcomes
https://t.co/tb8sVDtxOp
Editorial
https://t.co/DpgpyraYIT

Routine Double-Tap in SAPIEN 3 Ultra Resilia
https://t.co/BaU67xCF7g

Real-time Fluoroscopic analysis of underexpansion in balloon-expandable TAVR
https://t.co/lEfR4dXrTM
Editorial
https://t.co/kZVv6gpub4

[Jonathan Curio @CurioJonathan]

Insights into PVL post #TTVR at #PCRLV ⬆️
@PamelaGatto @alcantaramonica @dr_chrisallen @O_Azizy_MD @BenekiEirini @MiChen__ @juliendreyfus1 @jcecharte @DrGarot @cvnurselin @drtsakamoto @a_sorropago @TagliariPaula @m_taramasso @dr_tyxiong

[Jonathan Curio @CurioJonathan]

⭐New insights from TRIPLACE featured at #PCRLV: PVL after #TTVR by @AndreaScotti21 et al.

🎯 6.1% w/ >/= mod PVL (predicted by large RA, malpositioning, type IV morphology)
🎯>/= mod translated into ⬆️1y mort
➡️May have key implications for procedural optimization+device design

[Jonathan Curio @CurioJonathan]

RV remodelling data post Lux #TTVR from #PCRLV ⬆️
@PamelaGatto @alcantaramonica @dr_chrisallen @O_Azizy_MD @BenekiEirini @MiChen__ @juliendreyfus1 @jcecharte @DrGarot @cvnurselin @drtsakamoto @a_sorropago @TagliariPaula @m_taramasso @dr_tyxiong

[Jonathan Curio @CurioJonathan]

Latest Science for #treatTR featured at #PCRLV: RV remodelling after Lux- Valve #TTVR by Kobari et al.

🎯Sufficient+sustained TR reduction at 1y
🎯Translated into pos RV remodelling, espec in pt w/ TAPSE/sPAP > 0.3
➡️Prognostic implications of RV remodelling need to be studied

[Jonathan Curio @CurioJonathan]

Latest data on multivalve disease in #TTVR at #PCRLV⬆️
@PamelaGatto @alcantaramonica @dr_chrisallen @O_Azizy_MD @BenekiEirini @MiChen__ @juliendreyfus1 @jcecharte @DrGarot @cvnurselin @drtsakamoto @a_sorropago @TagliariPaula @m_taramasso @dr_tyxiong

[Jonathan Curio @CurioJonathan]

🚀Additional insights from TRISCEND + TRISCEND II #treatTR: Multivalve disease in #TTVR by @JennifervStein et al.

⭐Find the key takes of the study in the @PCRonline #PCRLV e-Poster⤵️